DR. MARC A. SHUMAN, M.D.
Osteopathic Medicine at Divisadero St, San Francisco, CA
License number
California G33090
Category
Osteopathic Medicine
Type
Internal Medicine
License number
California G33090
Category
Osteopathic Medicine
Type
Hematology
Address
Address
1600 Divisadero St, San Francisco, CA 94115
Phone
(415) 353-7171
(415) 353-7093 (Fax)
(415) 353-7093 (Fax)
Personal information
See more information about MARC A. SHUMAN at radaris.comName
Address
Phone
33368 Colorado St, Yucaipa, CA 92399
37 Claremont Blvd, San Francisco, CA 94127
400 Parnassus Ave, San Francisco, CA 94122
1600 Divisadero St, San Francisco, CA 94115
37 Claremont Blvd, San Francisco, CA 94127
Organization information
See more information about MARC A. SHUMAN at bizstanding.comMarc Shuman
37 Claremont Blvd, San Francisco, CA 94127
Categories:
Community & Civic Organizations
Phone:
(415) 476-2125 (Phone)
Marc Shuman MD
505 Parnassus Ave, San Francisco, CA 94122
Industry:
Internist
Phone:
(800) 844-5240 (Phone)
Marc Alan Shuman
Professional information
At University Of California, San Francisco
Position:
Professor at UCSF Medical Center, Professor of Medicine at University of California
Location:
San Francisco Bay Area
Industry:
Hospital & Health Care
Work:
UCSF Medical Center
since 1976
-
Professor
University of California
since 1976
-
Professor of Medicine
Education:
Jefferson Medical College of Thomas Jefferson University 1963 - 1967
MD, MEDICINE
MD, MEDICINE
Clinical Director At Qb3
Position:
Professor at University of California, Clinical Director at California Institute for Quantitative Biosciences
Location:
San Francisco Bay Area
Industry:
Research
Work:
University of California
-
Professor
California Institute for Quantitative Biosciences
since 2005
-
Clinical Director
Dr. Marc A Shuman, San Francisco CA - MD (Doctor of Medicine)
Specialties:
Hematology
Address:
1600 Divisadero St, San Francisco 94115
(415) 353-7171 (Phone), (415) 353-7093 (Fax)
(415) 353-7171 (Phone), (415) 353-7093 (Fax)
Certifications:
Hematology, 1974, Internal Medicine, 1972
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
1600 Divisadero St, San Francisco 94115
UCSF Medical Center at Mount Zion
1600 Divisadero St, San Francisco 94115
UCSF Medical Center at Mount Zion
1600 Divisadero St, San Francisco 94115
Education:
Medical School
Thomas Jefferson University
Graduated: 1967
Pennsylvania Hospital Of University Of Pennsylvania Health System
Hospital Of The University Of Pennsylvania
Barnes-Jewish Hospital
Thomas Jefferson University
Graduated: 1967
Pennsylvania Hospital Of University Of Pennsylvania Health System
Hospital Of The University Of Pennsylvania
Barnes-Jewish Hospital
Platelet Specific Therapeutic Compound And Method Of Treating
US Patent:
6022854, Feb 8, 2000
Filed:
Apr 17, 1995
Appl. No.:
8/425347
Inventors:
Marc A. Shuman - San Francisco CA
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
C07K 1900, A61K 3817
US Classification:
514 12
Abstract:
A therapeutic compound comprises a KGD-containing peptide, tandem repeats thereof, combinations thereof, or combinations thereof with an RGD-containing peptide or tandem repeats thereof, or peptide analogues or non-peptide organic analogues of the RGD and KGD tripeptides, and a pharmaceutical agent. A therapeutic composition comprises the compound of this invention and a pharmaceutically acceptable carrier. A polydeoxyribonucleotide comprises a DNA sequence, and a polyribonucleotide comprises an RNA sequence, encoding the compound of the invention, where the pharmaceutical agent is a peptide. A self-replicating DNA carries the polydeoxyribonucleotide described above and a transformed host cell comprises the self-replicating DNA. Therapeutic platelets are loaded with a therapeutic compound comprising a peptide comprising RGD or KGD, peptide analogues or organic analogues thereof, tandem repeats thereof, or combinations thereof, and a pharmaceutical agent operatively linked to the peptide. A method of delivering a pharmaceutical agent to a site afflicted with a disease comprises administering an effective amount of the therapeutic platelets or the therapeutic compound comprising RGD or KGD and a pharmaceutical agent.
Membrane Type Serine Protease 1 (Mt-Sp1) And Uses Thereof
US Patent:
7030231, Apr 18, 2006
Filed:
Sep 30, 1999
Appl. No.:
09/410362
Inventors:
Charles S. Craik - San Francisco CA, US
Toshihiko Takeuchi - San Francisco CA, US
Marc Shuman - San Francisco CA, US
Toshihiko Takeuchi - San Francisco CA, US
Marc Shuman - San Francisco CA, US
Assignee:
Catalyst Biosciences, Inc. - South San Francisco CA
International Classification:
C12N 15/11
US Classification:
536 231, 4353201, 435325, 435 691
Abstract:
This invention provides a novel membrane-type serine protease (designated MT-SP1) elevated expression of which is associated with cancer. In one embodiment, this invention provides a method obtaining a prognosis or of detecting or staging a cancer in an organism. The method involves providing a biological sample from the organism and detecting the level of a membrane type serine protease 1 (MT-SP1) in the sample, where an elevated level of the membrane-type serine protease, as compared to the level of the protease in a biological sample from a normal healthy organism indicates the presence or stage of the cancer.
Mt-Sp1 Serine Protease
US Patent:
2006009, May 11, 2006
Filed:
Oct 18, 2005
Appl. No.:
11/254185
Inventors:
Charles Craik - San Francisco CA, US
Toshihiko Takeuchi - San Francisco CA, US
Marc Shuman - San Francisco CA, US
Toshihiko Takeuchi - San Francisco CA, US
Marc Shuman - San Francisco CA, US
International Classification:
C12Q 1/68, G01N 33/574, C07H 21/04, C12P 21/06, C12N 9/64, C07K 16/40, C40B 40/10
US Classification:
435006000, 536023200, 435007230, 435069100, 435226000, 435320100, 435325000, 530388260
Abstract:
This invention provides a novel membrane-type serine protease (designated MT-SP1) elevated expression of which is associated with cancer. In one embodiment, this invention provides a method obtaining a prognosis or of detecting or staging a cancer in an organism. The method involves providing a biological sample from the organism and detecting the level of a membrane type serine protease 1 (MT-SP1) in the sample, where an elevated level of the membrane-type serine protease, as compared to the level of the protease in a biological sample from a normal healthy organism indicates the presence or stage of the cancer.
Mt-Sp1 Polynucleotides And Polypeptides
US Patent:
7227009, Jun 5, 2007
Filed:
Oct 18, 2005
Appl. No.:
11/253869
Inventors:
Charles S. Craik - San Francisco CA, US
Toshihiko Takeuchi - San Francisco CA, US
Marc Shuman - San Francisco CA, US
Toshihiko Takeuchi - San Francisco CA, US
Marc Shuman - San Francisco CA, US
Assignee:
Catalyst Biosciences, Inc. - South San Francisco CA
International Classification:
C12N 15/11
US Classification:
536 231, 4353201, 435325, 435 691
Abstract:
This invention provides a novel membrane-type serine protease (designated MT-SP1) elevated expression of which is associated with cancer. In one embodiment, this invention provides a method obtaining a prognosis or of detecting or staging a cancer in an organism. The method involves providing a biological sample from the organism and detecting the level of a membrane type serine protease 1 (MT-SP1) in the sample, where an elevated level of the membrane-type serine protease, as compared to the level of the protease in a biological sample from a normal healthy organism indicates the presence or stage of the cancer.
Methods And Compositions For The Diagnosis Of Bloodclots Using Plasminogen Activator
US Patent:
4663146, May 5, 1987
Filed:
Jul 29, 1983
Appl. No.:
6/518438
Inventors:
Michael J. Morser - San Francisco CA
Marc A. Shuman - San Francisco CA
Marc A. Shuman - San Francisco CA
Assignee:
Codon Genetic Engineering Laboratories - Brisbane CA
International Classification:
A61K 4900, A61K 4300
US Classification:
424 11
Abstract:
Methods for detecting fibrin or fibrin clots in a host suspected of producing fibrin by: introducing labeled tissue plasminogen activator or a binding site fragment derived therefrom into the host's bloodstream and assaying for the presence of concentrations of labeled tissue plasminogen activator in said host. Also provided are kits for practicing the invention.
Antibodies To Mt-Sp1 Serine Protease
US Patent:
2009015, Jun 18, 2009
Filed:
Jan 14, 2008
Appl. No.:
12/014067
Inventors:
Charles S. Craik - San Francisco CA, US
Toshihiko Takeuchi - San Francisco CA, US
Marc Shuman - San Francisco CA, US
Toshihiko Takeuchi - San Francisco CA, US
Marc Shuman - San Francisco CA, US
International Classification:
A61K 39/395, C07K 16/00, C12N 1/00, G01N 33/573, A61P 35/00
US Classification:
4241331, 5303891, 5303881, 5303873, 435243, 435 74, 4241301
Abstract:
This invention provides a novel membrane-type serine protease (designated MT-SP1) elevated expression of which is associated with cancer. In one embodiment, this invention provides a method obtaining a prognosis or of detecting or staging a cancer in an organism. The method involves providing a biological sample from the organism and detecting the level of a membrane type serine protease 1 (MT-SP1) in the sample, where an elevated level of the membrane-type serine protease, as compared to the level of the protease in a biological sample from a normal healthy organism indicates the presence or stage of the cancer.
Mt-Sp1 Polypeptides
US Patent:
2008005, Feb 28, 2008
Filed:
Jan 31, 2007
Appl. No.:
11/669725
Inventors:
Charles Craik - San Francisco CA, US
Toshihiko Takeuchi - San Francisco CA, US
Marc Shuman - San Francisco CA, US
Toshihiko Takeuchi - San Francisco CA, US
Marc Shuman - San Francisco CA, US
International Classification:
C07K 16/00
US Classification:
530350000
Abstract:
This invention provides a novel membrane-type serine protease (designated MT-SP1) elevated expression of which is associated with cancer. In one embodiment, this invention provides a method obtaining a prognosis or of detecting or staging a cancer in an organism. The method involves providing a biological sample from the organism and detecting the level of a membrane type serine protease 1 (MT-SP1) in the sample, where an elevated level of the membrane-type serine protease, as compared to the level of the protease in a biological sample from a normal healthy organism indicates the presence or stage of the cancer.